HC Wainwright Forecasts Lower Earnings for TG Therapeutics

Key Points

• HC Wainwright cut its Q2 2026 EPS forecast for TG Therapeutics to $0.20 from $0.27 and issued multi‑year EPS projections (e.g., FY2027 $1.60 and FY2030 $3.66).
• TG Therapeutics last reported $0.14 EPS versus analysts' $0.35 estimate while revenue of $192.6M was roughly in line and rose 78% year‑over‑year, leaving margins and ROE unusually high for the quarter.
• The stock is trading up (~4.6%) with a market cap of about $5.9B, a P/E of 13.34, and a consensus analyst rating of “Moderate Buy” with a $50 consensus target price.

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Stock analysts at HC Wainwright reduced their Q2 2026 earnings per share (EPS) estimates for TG Therapeutics in a report issued on Monday, April 20th. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will earn $0.20 per share for the quarter, down from their previous forecast of $0.27. The consensus estimate for TG Therapeutics' current full-year earnings is $1.39 per share. HC Wainwright also issued estimates for TG Therapeutics' Q3 2026 earnings at $0.25 EPS, Q4 2026 earnings at $0.34 EPS, FY2027 earnings at $1.60 EPS, FY2028 earnings at $2.11 EPS, FY2029 earnings at $2.71 EPS and FY2030 earnings at $3.66 EPS.

TGTX has been the subject of a number of other research reports. Cantor Fitzgerald reissued an "overweight" rating on shares of TG Therapeutics in a report on Wednesday, January 14th. Wall Street Zen downgraded TG Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, February 14th. Weiss Ratings reissued a "hold (c+)" rating on shares of TG Therapeutics in a report on Monday, December 29th. JPMorgan Chase & Co. reduced their price target on TG Therapeutics from $49.00 to $46.00 and set an "overweight" rating for the company in a report on Monday, February 2nd. Finally, The Goldman Sachs Group increased their price target on TG Therapeutics from $37.00 to $39.00 and gave the company a "neutral" rating in a report on Thursday, January 15th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, TG Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $50.00.

TG Therapeutics Trading Up 4.6%

Shares of TGTX opened at $36.96 on Tuesday. The company has a market capitalization of $5.90 billion, a P/E ratio of 13.34 and a beta of 1.76. TG Therapeutics has a one year low of $25.28 and a one year high of $46.48. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.29 and a current ratio of 4.10. The stock has a 50-day moving average price of $31.02 and a 200 day moving average price of $31.46.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.35 by ($0.21). The business had revenue of $192.57 million during the quarter, compared to analysts' expectations of $192.15 million. TG Therapeutics had a net margin of 72.56% and a return on equity of 101.12%. The company's revenue for the quarter was up 78.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.15 EPS.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of TGTX. Danske Bank A S acquired a new stake in shares of TG Therapeutics during the 3rd quarter worth approximately $25,000. Optiver Holding B.V. raised its position in shares of TG Therapeutics by 3,485.7% during the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 732 shares during the period. Bessemer Group Inc. raised its position in shares of TG Therapeutics by 117.1% during the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 486 shares during the period. Salomon & Ludwin LLC acquired a new stake in shares of TG Therapeutics during the 3rd quarter worth approximately $34,000. Finally, Stone House Investment Management LLC acquired a new stake in shares of TG Therapeutics during the 3rd quarter worth approximately $36,000. Institutional investors own 58.58% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company's research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.